HENRY J. LEHNHOFF JR., M.D., F.A.C.P.
Patients receiving androgen therapy for metastatic carcinoma of the breast have been observed to show increased erythropoietic activity of a degree which may raise subnormal blood counts to normal or polycythemic levels. Bone marrow examination in these patients revealed increased erythropoietic activity, although no blood transfusions or hematinics were administered. The medication employed has been testosterone proprionate, given intramuscularly in doses of 50 to 100 mg. three times a week, or in equivalent oral doses. The phenomenon occurs in 16 to 64% of the patients treated. Why some patients respond and some do not is not known. The concomitant administration
LEHNHOFF HJ. ANDROGEN THERAPY FOR REFRACTORY ANEMIA: REPORT OF A CASE ASSOCIATED WITH THYMOMA1. Ann Intern Med. ;53:1059–1064. doi: 10.7326/0003-4819-53-5-1059
Download citation file:
Published: Ann Intern Med. 1960;53(5):1059-1064.
Hematology/Oncology, Red Cell Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use